🔴 Marker Therapeutics is trading 5% down — cause remains unclear

Marker Therapeutics is trading at $1.14, down 5.00%, with the reason for the October 20 decline unclear.

• On October 19, Marker Therapeutics announced a $2.6 million FDA grant to support a Phase 1 MT-601 pancreatic cancer study; that earlier positive announcement does not establish the cause of the decline.
• Biotech was up 2.10%, so the provided sector context does not explain the drop as a sector-wide move.